# Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

> **NCT00106340** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3118 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** vildagliptin
- **DRUG:** glimepiride
- **DRUG:** Metformin
- **DRUG:** Vildagliptin matching placebo
- **DRUG:** Glimepiride matching placebo

## Key facts

- **NCT ID:** NCT00106340
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2008-05
- **Final completion:** 2008-05-20
- **Target enrollment:** 3118 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106340, "Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00106340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*